medigraphic.com
ISSN 1561-3011 (Digital)

2013, Número 1

Siguiente >>

Rev Cubana Invest Bioméd 2013; 32 (1)


Hígado graso no alcohólico como señal de aterosclerosis

Piñeiro LR, Fernández-Brito RJE

Idioma: Español
Referencias bibliográficas: 40
Paginas:
Archivo PDF: 182.27 Kb.


RESUMEN

Los pacientes con Hígado Graso No Alcohólico (HGNA), presentan un incremento en la mortalidad por enfermedad coronaria aterosclerótica, siendo la misma, la segunda causa más frecuente de muerte en los pacientes con HGNA. En general, el Engrosamiento de la Íntima Media Carotídea (EIMC), el cual constituye una evidencia de aterosclerosis subclínica, es mayor en los pacientes con HGNA que en las personas sanas. Los individuos con HGNA están en riesgo de aterosclerosis carotídea, independientemente de la presencia del Síndrome Metabólico y de factores clásicos de riesgo coronario aterosclerótico, por lo tanto la detección del HGNA, nos debe alertar de la existencia del incremento del riesgo de enfermedad aterosclerótica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1-Abel T, Fehér J. [Non-alcoholic fatty liver disease and cardiovascular risk] Orv Hetil.2008;149(28):1299-305.

  2. 2- Papandreou D, Rousso I, Mavromichalis I.Update on non-alcoholic fatty liver disease in children. Clin Nutr. 2007;26(4):409-15.

  3. 3 Pacheco Torres L, Piñeiro R, Fragoso T, Valdés MC, Martínez R. Hígado graso no alcohólico en niños obesos. Rev Cubana Pediatr [revista en la Internet]. 2006 Mar [citado 2012 Mar 23] ; 78(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75312006000100002&lng=es.

  4. 4- Piñeiro R, Pacheco L. Dìaz L. Insulin resistance. The cause of fatty liver disease in obese adolescents. Journal Pediatric Gastroenterology Nutrition (JPGN) Suppl. 2003; 37 (3): 343.

  5. 5-Edens MA, Kuipers F, Stolk RP.Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev. 2009;10(4):412-9.

  6. 6-Ardigò D, Franzini L, Valtueña S, Numeroso F, Piatti PM, Monti L, Reaven GM, .The increase in plasma PAI-1 associated with insulin resistance may be mediated by the presence of hepatic steatosis. Atherosclerosis. 2010;208(1):240-5.

  7. 7-Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42(5):320-30.

  8. 8-Adams LA, Angulo P Recent concepts in non-alcoholic fatty liver diseaseDiabet Med. 2005;22(9):1129-33.

  9. 9-Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H, Gray-McGuire C, Schauer PR, Gupta M, Feldstein AE, Hazen SL, Stein CM. Obesity (Silver Spring). 2009 ;17(9):1696-701.

  10. 10- Papandreou D, Rousso I, Mavromichalis I..Update on non-alcoholic fatty liver disease in children. Clin Nutr. 2007;26(4):409-15.

  11. 11-Assy N, Djibre A, Farah R, Grosovski M, Marmor A.Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010;254(2):393-400.

  12. 12-Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2007;13(26):3540-53.

  13. 13-Björnsson E.The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2008;54(1):7-18.

  14. 14-Sookoian S, Pirola CJ.Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review.J Hepatol. 2008;49(4):600-7.

  15. 15-Lizardi-Cervera J, Aguilar-Zapata D.Nonalcoholic fatty liver disease and its association with cardiovascular disease. Ann Hepatol. 2009;8 Suppl 1:S40-3.

  16. 16-Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G.Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30(5):1212-8.

  17. 17-Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M.Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008 ;51(3):444-50.

  18. 18-Targher G, Bertolini L, Padovani R, Poli F, Scala L, Zenari L, Zoppini G, Falezza G.Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. J Endocrinol Invest. 2006 ;29(1):55-60.

  19. 19-Karakurt F, Carlioglu A, Koktener A, Ozbek M, Kaya A, Uyar ME, Kasapoglu B, Ilhan A.Relationship between cerebral arterial pulsatility and carotid intima media thickness in diabetic and non-diabetic patients with non-alcoholic fatty liver disease. J Endocrinol Invest. 2009 ;32(1):63-8.

  20. 20-Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E.Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol. 2005;25(5):1045-50.

  21. 21-Choi SY, Kim D, Kang JH, Park MJ, Kim YS, Lim SH, Kim CH, Lee HS..[Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis]. Korean J Hepatol. 2008;14(1):77-88.

  22. 22- Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G.Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006 ;29(6):1325-30.

  23. 23-Sung KC, Ryan MC, Wilson AM.The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis. 2009;203(2):581-6

  24. 24-Targher G.Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med. 2007 ;24(1):1-6.

  25. 25-Vlachopoulos C, Manesis E, Baou K, Papatheodoridis G, Koskinas J, Tiniakos D, Aznaouridis K, Archimandritis A, Stefanadis C. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study.Am J Hypertens. 2010; 23(11):1183-9.

  26. 26-Salvi P, Ruffini R, Agnoletti D, Magnani E, Pagliarani G, Comandini G, Praticò A, Borghi C, Benetos A, Pazzi P Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study J Hypertens. 2010; 28(8):1699-707.

  27. 27-Rosin BL.The progression of cardiovascular risk to cardiovascular disease. Rev Cardiovasc Med. 2007;8 Suppl 4:S3-8.

  28. 28-Krawczyk K, Szczesniak P, Kumor A, Jasinska A, Omulecka A, Pietruczuk M, Orszulak-Michalak D, Sporny S, Malecka-Panas EJ Physiol Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).Pharmacol. 2009;60 Suppl 3:71-5.

  29. 30-Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM Adipokines and cytokines in non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2008;27(5):412-21.

  30. 31-Khashab MA, Liangpunsakul S, Chalasani N.Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep. 2008;10(1):73-80.

  31. 32-Alper AT, Hasdemir H, Sahin S, Ontürk E, Akyol A, Nurkalem Z, , Erdinler I, Gürkan K.The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars. 2008 ;36(6):376-81.

  32. 33- Adibi P, Sadeghi M, Mahsa M, Rozati G, Mohseni M.Prediction of coronary atherosclerotic disease with liver transaminase level. Liver Int. 2007;27(7):895-900.

  33. 34-Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009 ;6(6):399-409.

  34. 35-Blüher M. The inflammatory process of adipose tissue.Pediatr Endocrinol Rev. 2008 ;6(1):24-31.

  35. 36-Calabro P, Yeh ET.Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. Subcell Biochem. 2007;42:63-91.

  36. 37-Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G.Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med. 2005 ;22(10):1354-8.

  37. 38-Wang CC, Lin SK, Tseng YF, Hsu CS, Tseng TC, Lin HH, Wang LY, Kao JH Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease..J Gastroenterol Hepatol. 2009;24(8):1411-6.

  38. 39-Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, Diamant M. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study Atherosclerosis. 2007 ;191(2):391-6.

  39. 40-Wang CC, Lin SK, Tseng YF, Hsu CS, Tseng TC, Lin HH, Wang LY, Kao JH. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2009;24(8):1411-6.

  40. 41-Koskinen J, Magnussen CG, Kähönen M, Loo BM, Marniemi J, Jula A, Saarikoski LA, Huupponen R, Viikari JS, Raitakari OT, Juonala M. .Association of liver enzymes with metabolic syndrome and carotid atherosclerosis in young adults. The Cardiovascular Risk in Young Finns Study. Ann Med. 2012;44(2):187-95.




2020     |     www.medigraphic.com